Russell Investments Group
RAPT

Russell Investments Group’s RAPT Therapeutics RAPT Stock Holding History

Russell Investments Group’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,080
Closed -$27.9K – 4244
2025
Q3 		$27.9K Hold
1,080
– – ﹤0.01% 3491
2025
Q2 		$8.64K Sell
1,080
-772
-42% -$5.89K ﹤0.01% 3360
2025
Q1 		$18.1K Buy
1,852
+95
+5% +$934 ﹤0.01% 3132
2024
Q4 		$22.2K Buy
1,757
+1,360
+343% +$17.3K ﹤0.01% 2980
2024
Q3 		$6.39K Buy
397
+225
+131% +$4.55K ﹤0.01% 3174
2024
Q2 		$4.18K Buy
+172
New +$7.95K ﹤0.01% 3253
2023
Q4 		– Sell
-73
Closed -$9.66K – 3292
2023
Q3 		$9.66K Sell
73
-68
-48% -$11.1K ﹤0.01% 3009
2023
Q2 		$21K Hold
141
– – ﹤0.01% 2834
2023
Q1 		$20.6K Buy
141
+73
+107% +$14.8K ﹤0.01% 2808
2022
Q4 		$10.8K Hold
68
– – ﹤0.01% 2842
2022
Q3 		$13K Buy
+68
New +$12.9K ﹤0.01% 2847
2020
Q4 		– Sell
-1,263
Closed -$325K – 3162
2020
Q3 		$325K Buy
+1,263
New +$280K ﹤0.01% 2581

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Russell Investments Group's RAPT Position: Q4 2025 in Review

Russell Investments Group sold out of RAPT Therapeutics (RAPT) in Q4 2025, closing a stake of 1,080 shares — an estimated $27.9K sold.

Russell Investments Group first reported a position in RAPT in Q3 2020 and held it in 12 quarters. The position peaked at $325K in Q3 2020. 105 funds tracked by Wall St. Rank hold RAPT as of Q4 2025.

  • Russell Investments Group reported no remaining RAPT Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Russell Investments Group sold 1,080 RAPT Therapeutics shares in Q4 2025, an estimated $27.9K.
  • Russell Investments Group first reported a position in RAPT Therapeutics in Q3 2020 and held it in 12 quarters.
  • Russell Investments Group's RAPT Therapeutics position peaked at $325K in Q3 2020.
  • 105 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2025.

Based on Russell Investments Group's 13F filing for Q4 2025, filed 17 Feb 2026.